Cannabis use among pregnant and postpartum women in the United States has risen sharply over the past decade. Some surveys suggest that marijuana is now one of the most commonly used substances during pregnancy, with many women turning to it to manage nausea, anxiety, or sleep difficulties. As cannabis becomes more socially accepted and legally available across many states, a concerning gap has emerged between public perception and what medical research actually shows.
Many people assume that because cannabis is natural or legal, it must be safe. However, medical evidence tells a more complicated story, particularly when a developing baby is involved.
This article draws on current scientific and clinical research to provide clear, evidence-based information. It covers both the pregnancy period and the postpartum phase, including breastfeeding, to give a complete picture of the known risks.
How Common Is THC Use During Pregnancy?
Cannabis is the most commonly used illicit substance among pregnant women in the United States. According to the CDC and SAMHSA (Substance Abuse and Mental Health Services Administration), approximately 7% of pregnant women report using cannabis, with rates rising sharply in states where recreational use has been legalized.
Many women turn to cannabis to manage uncomfortable pregnancy symptoms — particularly nausea, anxiety, chronic pain, and sleep difficulties. Because dispensaries are accessible and products are widely marketed as “natural,” some women assume cannabis is safe during pregnancy. This assumption is medically unsupported.
The following table illustrates how cannabis use rates during pregnancy have shifted before and after legalization across different trimesters and age groups.
| Category | Pre-Legalization Rate | Post-Legalization Rate |
|---|---|---|
| First Trimester | ~6% | ~11% |
| Second Trimester | ~3% | ~5% |
| Third Trimester | ~2% | ~4% |
| Age Group | ||
| Teens (15–19) | ~12% | ~22% |
| Ages 20–29 | ~8% | ~15% |
| Ages 30+ | ~3% | ~6% |
Rates are consistently highest among younger women and during the first trimester, often before a pregnancy is confirmed. Self-medicating with cannabis without clinical guidance carries serious risks that no trimester is free from.
Understanding THC: How It Works in the Body and Why Pregnancy Changes Everything
THC, short for delta-9-tetrahydrocannabinol, is the main psychoactive compound in cannabis — the chemical responsible for the “high” people experience. Once consumed, THC enters the bloodstream and binds to receptors in the endocannabinoid system, a network of chemical signals that helps regulate mood, appetite, memory, and pain throughout the body.
During pregnancy, however, THC does not stay confined to the mother’s body. Because THC is fat-soluble — meaning it dissolves in fat rather than water — it passes easily through the placenta, the organ that connects mother and baby, directly entering fetal circulation.
This matters enormously because the fetal endocannabinoid system is not simply a smaller version of an adult’s. It plays an active, critical role in guiding early brain development, helping direct how neurons form, migrate, and connect.
Pathway of THC Exposure
The following pathway illustrates how THC travels from the mother to the developing fetus.
- Maternal THC use
- Bloodstream
- Crosses placenta
- Enters fetal circulation
- Reaches fetal brain
Unlike an adult brain, the developing fetal brain lacks mature metabolic defenses to process and eliminate THC efficiently, meaning THC accumulates in fetal tissues and prolongs exposure far beyond what the mother herself experiences.
Medical Risks of THC Use During Pregnancy
Understanding the medical risks of THC use during pregnancy requires looking at how cannabis affects the developing baby at different stages of growth, as well as how it impacts the mother’s own health.
Fetal and Neonatal Risks
THC crosses the placenta, meaning it travels directly from the mother’s bloodstream into the baby’s environment. This exposure is linked to intrauterine growth restriction (IUGR) — a condition where the baby does not grow at a normal rate inside the womb — as well as low birth weight, which increases a newborn’s vulnerability to infection and developmental delays. Research also connects prenatal THC exposure to a higher likelihood of preterm birth, meaning delivery before 37 weeks, when critical organ development is still incomplete. Emerging data is beginning to examine links to stillbirth, though researchers emphasize more study is needed. Additionally, some newborns exposed to THC in the womb display Neonatal Abstinence Syndrome (NAS) — withdrawal symptoms such as tremors, irritability, poor feeding, and disrupted sleep patterns.
Neurodevelopmental Risks
Long-term studies, including the large-scale Adolescent Brain Cognitive Development (ABCD) Study, reveal that children exposed to THC before birth show measurable differences in brain development. These include impaired executive function (difficulty planning, organizing, and controlling impulses), attention deficits and ADHD-like symptoms, and greater risk of anxiety and depression in later childhood. Academic performance also tends to be lower in this population.
Maternal Risks
THC use during pregnancy carries direct risks for the mother as well. It may worsen complications related to hyperemesis gravidarum — severe, persistent nausea and vomiting during pregnancy — rather than safely relieving them. THC can also interact unpredictably with prenatal vitamins and prescribed medications. Furthermore, THC affects the brain’s reward and bonding chemistry, potentially interfering with maternal-fetal bonding after birth.
Summary of Risks
The table below provides an overview of the key risk categories associated with prenatal THC exposure and the current strength of evidence for each.
| Risk Category | Potential Outcome | Evidence Level |
|---|---|---|
| Fetal Growth | IUGR, Low Birth Weight | Strong (multiple cohort studies) |
| Neurological | Cognitive delay, ADHD traits | Moderate–Strong (longitudinal) |
| Neonatal | Withdrawal symptoms | Moderate |
| Maternal | Medication interactions | Emerging |
No established “safe” level of THC use during pregnancy currently exists.
THC Use and Morning Sickness: Addressing a Common Justification
Nausea and vomiting during pregnancy — clinically called nausea and vomiting of pregnancy (NVP) — affects up to 80% of pregnant women. In its most severe form, known as hyperemesis gravidarum, it causes extreme, persistent vomiting that can lead to dangerous dehydration and weight loss. This suffering is real, and the desire for fast relief is completely understandable.
However, no major medical organization — including the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), or the World Health Organization (WHO) — recommends cannabis or THC for pregnancy-related nausea. The risks to fetal brain development outweigh any perceived benefit.
The following table outlines clinically supported treatment options for pregnancy-related nausea, organized by level of intervention.
| Treatment Level | Options |
|---|---|
| First-line | Dietary changes, ginger supplements, small frequent meals, hydration |
| Second-line | Vitamin B6 (pyridoxine) alone or combined with doxylamine (Unisom) |
| Third-line | Prescription antiemetics: Ondansetron (Zofran), Metoclopramide — discussed with your OB/GYN |
| Severe cases | IV hydration and hospitalization when needed |
These options have established safety profiles studied in pregnant women. If nausea feels unmanageable, speaking openly with your healthcare provider ensures you receive effective, evidence-based relief that protects both you and your baby.
Postpartum Use and Breastfeeding: What the Evidence Shows
Many women who avoided cannabis during pregnancy wonder whether resuming use after delivery is safer, especially while breastfeeding. The assumption is understandable — the baby is no longer physically connected to the mother’s body. However, this reasoning overlooks a critical biological reality: THC passes directly into breast milk.
Research shows that THC concentrates in breast milk at levels roughly eight times higher than those found in the mother’s blood. This happens because THC is highly fat-soluble, meaning it binds easily to the fat-rich composition of breast milk. Once consumed, THC can remain detectable in breast milk for up to six days after a single use — and even longer in chronic users whose body fat has accumulated significant THC stores over time.
When infants feed on THC-containing breast milk, the consequences can be measurable. Reported effects include unusual sedation, altered feeding patterns, and reduced muscle tone. More concerning is the potential impact on infant brain development during a period of rapid neurological growth. No established “safe” level of infant THC exposure through breast milk has ever been identified by researchers.
Postpartum mental health is a genuinely serious concern. Postpartum depression (PPD) and anxiety affect many new mothers, and it is important to acknowledge these struggles without judgment. However, THC is not a clinically validated or safe treatment for PPD. Evidence-based options include cognitive behavioral therapy, antidepressant medications compatible with breastfeeding, peer support groups, and consultations with mental health professionals — all of which carry established safety profiles.
Both the American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) explicitly advise against cannabis use during breastfeeding.
THC vs. Alcohol in Breast Milk: A Comparison
The table below compares key characteristics of THC and alcohol in breast milk to highlight important differences in their risks and clearance.
| Factor | THC in Breast Milk | Alcohol in Breast Milk |
|---|---|---|
| Clearance time | Up to 6+ days | ~2–3 hours per drink |
| Fat solubility | Very high | Low |
| Infant CNS impact | Significant | Dose-dependent |
| Safe threshold established | No | No (but timing guidance exists) |
These differences underscore why THC poses a uniquely prolonged and difficult-to-manage risk for breastfeeding infants compared to other substances.
Screening, Disclosure, and the Patient-Provider Relationship
Obstetricians, gynecologists, and midwives routinely screen for cannabis use during prenatal visits. Screening typically involves two methods: urine toxicology testing, which detects THC metabolites in the body, and structured self-report questionnaires where patients are asked directly about substance use. Both methods help providers build a complete picture of a patient’s health.
Many pregnant individuals hesitate to disclose cannabis use due to real fears: social stigma, judgment from medical staff, legal consequences, or concern that child protective services may become involved. These fears are understandable, but staying silent can prevent providers from delivering the safest possible care.
Disclosure does not automatically trigger punishment. When cannabis use is reported, healthcare providers typically respond by increasing monitoring — such as ordering additional growth ultrasounds or non-stress tests (NSTs), which track fetal heart rate and movement. Providers may also connect patients with counseling, social work, or substance use support services. The goal is always a non-judgmental care plan tailored to the individual.
Both the American College of Obstetricians and Gynecologists (ACOG) and the U.S. Preventive Services Task Force (USPSTF) recommend universal screening for substance use during pregnancy.
Mandatory reporting laws vary significantly by state. Some states require providers to report confirmed substance use, while others do not. Patients are encouraged to ask their provider directly about local policies so they can make fully informed decisions about disclosure.
Special Considerations: Marginalized Populations and Disparities in Cannabis Research
Research on cannabis use during pregnancy has not affected all women equally. Black, Indigenous, and low-income women are disproportionately subjected to drug testing, child welfare investigations, and criminal penalties for cannabis use during pregnancy — even when use rates are similar across racial groups. This unequal enforcement creates serious barriers to honest conversations with healthcare providers.
Compounding this problem, most historical studies on prenatal cannabis exposure lacked racial and ethnic diversity, meaning the data does not fully represent all communities. Gaps in research make it harder to understand how outcomes may differ across populations.
Culturally competent, non-punitive care is essential. Every pregnant person deserves access to mental health support, effective nausea treatment, and community resources — regardless of income or background. Healthcare systems must work to eliminate stigma and ensure that fear of legal consequences never prevents someone from seeking safe, honest medical care.
Guidance for Partners, Family Members, and Support Networks
Pregnancy and postpartum care are not solo journeys. Everyone sharing a home with a pregnant or postpartum person plays a meaningful role in protecting both mother and baby — including how they personally handle cannabis use.
Secondhand and thirdhand smoke exposure are real concerns. Secondhand smoke means inhaling cannabis smoke directly from someone nearby. Thirdhand exposure refers to toxic residue that clings to furniture, clothing, and walls long after smoking has stopped. Both can introduce harmful compounds into a pregnant person’s environment without their direct use.
Partners who use cannabis at home should take this seriously. Smoking or vaping indoors — even in another room — can affect air quality and surface safety throughout the entire living space.
Family members can actively support abstinence by avoiding cannabis use around the pregnant person, helping reduce stress through practical assistance, and encouraging healthy coping routines like walks, cooking together, or relaxation activities.
Attending prenatal appointments together is one of the most impactful steps a partner or family member can take, ensuring everyone receives the same accurate safety information directly from healthcare providers.
Quick-Reference Tips for Partners and Family Members
The following tips offer practical steps that partners and family members can take to support a safe environment during pregnancy and the postpartum period.
- Keep cannabis use entirely out of shared living spaces
- Never smoke or vape near a pregnant or postpartum person
- Offer to join them in abstaining throughout pregnancy
- Support and attend prenatal care appointments together
Taking these steps consistently helps create a healthier, safer home environment for both the mother and the developing baby.
When to Seek Help: Resources and Next Steps
If you have questions or concerns about cannabis use during pregnancy or while breastfeeding, the most important first step is talking honestly with your OB/GYN or midwife. These conversations are confidential and judgment-free — your care team’s only goal is supporting your health and your baby’s safety.
Several types of support are available depending on your needs:
- Substance use counseling – The SBIRT model (Screening, Brief Intervention, and Referral to Treatment) helps identify concerns early and connect you with appropriate care.
- Mental health services – Therapists and counselors can address anxiety, depression, or stress that may be driving cannabis use.
- Peer support and community programs – Connecting with others who share similar experiences can reduce isolation and build confidence.
The following national resources offer free, confidential support for individuals seeking help during pregnancy and the postpartum period.
| Organization | Contact |
|---|---|
| SAMHSA National Helpline | 1-800-662-4357 (free, confidential, 24/7) |
| Postpartum Support International (PSI) | postpartum.net |
| CDC Pregnancy Resources | cdc.gov/pregnancy |
Reaching out early makes a meaningful difference. Whether you are currently pregnant, newly postpartum, or simply planning ahead, proactive conversations with your care team give you the best chance at a healthy outcome for both you and your child.
Conclusion
The medical consensus is clear and consistent: no amount of THC has been proven safe during pregnancy or while breastfeeding. The risks to fetal brain development, birth outcomes, and infant health are real, well-documented, and serious enough that every major medical organization recommends complete avoidance.
At the same time, the discomforts that drive some women toward cannabis — persistent nausea, anxiety, depression, and chronic pain — are genuine and deserve real attention. These struggles are valid, and help is available. Clinically approved, evidence-based treatments exist for each of these conditions and can be used safely during pregnancy and the postpartum period.
You deserve accurate information, not judgment. When you understand the risks clearly, you are empowered to make decisions that protect both yourself and your child. Your healthcare provider is your partner in finding safe, effective solutions every step of the way.